 
BSEM: From Profitable Regenerative Leader to Advanced Wound Care Powerhouse with a Nasdaq Uplisting on the Horizon. BioStem Technologies (OTCQB: BSEM) continues to separate itself from the small-cap MedTech pack with seven straight profitable quarters, FDA-registered manufacturing, and clinically proven BioREtain® technology that drives superior healing outcomes in diabetic foot ulcers. The recent acquisition of BioTissue’s surgical and wound care business adds $29 million in revenue, a national sales network, and immediate access to hospital and surgical settings, creating a direct path into acute and advanced wound care markets. With early adoption reflected in 40% year-over-year unit growth, a robust $300–$350 million market opportunity, and a potential Nasdaq uplisting in mid-2026, BSEM is executing on every element of a high-growth MedTech strategy. With a $25.50 price target from Zacks, BSEM stands out as a small-cap MedTech name with significant upside potential, especially as it prepares for a potential Nasdaq uplisting in 2026. Strong financial discipline, expanding commercial reach, and validated clinical results make BSEM a rare small-cap story to keep an eye on. See how BSEM is redefining the future of advanced and acute wound care in 2026 while building shareholder value
This Month's Exclusive Story Warner Bros. Rejects Paramount's Offer—How It Affects WBD, NFLX, PSKYBy Leo Miller. Publication Date: 1/9/2026. 
In Brief- Warner Bros. Discovery rose more than 170% in 2025, leading S&P 500 communications stocks.
- Following the Warner Bros.-Netflix deal, Paramount Skydance is continuing to pursue Warner Bros.
- However, WBD isn't budging. See what its latest rejection of PSKY's offer means for all three stocks.
Shares of entertainment giantWarner Bros. Discovery (NASDAQ: WBD) had a landmark year in 2025, rising roughly 173% and finishing as the best-performing communications stock in the S&P 500 Index. The battle to buy Warner Bros. was the dominant driver of that performance. Warner Bros. and Netflix (NASDAQ: NFLX) reached a deal in December when the streaming leader agreed to buy most of WBD for an enterprise value of about $82.7 billion. Have you heard about this sub $1 company that is making people "Superhumans"?
Investors have already started flooding in to take advantage of this while the company is still private.
But this opportunity won't be around forever... Click here to see the sub $1 'Superhuman' AI Stock However, Paramount Skydance (NASDAQ: PSKY) has continued to press its own bid, recently offering to buy all of WBD at an enterprise value of $108.4 billion. Despite Oracle (NYSE: ORCL) founder Larry Ellison backstopping the proposal, Warner Bros. urged shareholders to reject the offer. Below, we break down what this development means for the three companies involved. WBD Could Benefit From a Renewed Bidding WarFor Warner Bros. Discovery, little changes for now. The company is continuing with its plan to sell its streaming, television and movie production assets to Netflix. WBD will also spin out its cable TV channels into Discovery Global, with WBD shareholders receiving new Discovery Global shares after the Netflix deal closes. Netflix's share price at closing will affect the value WBD shareholders receive, and market valuation of Discovery Global will also factor into the total consideration. A likely estimate of the total value per WBD share falls between $28 and $33. Paramount's offer, by contrast, is an all-cash $30 per share for the entire company. It is not contingent on Paramount's share price and would not require the cable-channel spin-off. Warner Bros. has signaled a Paramount deal could still happen, but only if Paramount raises its price. That leaves room for a renewed bidding war, which could push WBD shares higher. On Jan. 8, Paramount Skydance reaffirmed its $30 offer, though that stance could change. NFLX Hopes the Status Quo HoldsNetflix remains in the driver's seat in the race to buy WBD. The deal would significantly increase Netflix's share of the TV streaming market and give it control of valuable intellectual property. But financing the deal would be substantial: Bloomberg Intelligence estimates Netflix would need to add roughly $60 billion in debt. Beyond financing risks, the transaction would likely face intense antitrust scrutiny that could affect its chance of regulatory approval. Markets have reacted negatively so far. Since the official announcement on Dec. 5, 2025, Netflix shares were down nearly 10% as of the Jan. 8 close. Still, if the deal closes and Netflix successfully integrates WBD, the long-term benefits could be substantial. A renewed bidding war would be against Netflix's interests because it could force Netflix to pay more than its original agreement. WBD appears committed to maximizing shareholder value, and it is uncertain how much higher Paramount might be willing to go. PSKY Must Pony Up to Win WBDParamount Skydance is pursuing a hostile takeover, asking WBD shareholders to sell — or "tender" — their shares to PSKY. If a majority of WBD shares are tendered, Paramount could complete the acquisition. Warner Bros. has recommended shareholders not tender to Paramount, and so far investor response has been minimal. There are about 2.6 billion WBD shares outstanding, and shareholders would need to tender more than half to PSKY for its offer to succeed. Bloomberg Intelligence analyst Geetha Ranganathan says investors have only tendered roughly 500,000 shares to date — far from the necessary threshold. That leaves Paramount with limited options: either continue to press the tender offer and hope shareholders defect from WBD's recommendation, or increase its bid. Ranganathan suggests Warner Bros. may be seeking a $34-per-share offer to change its stance. Could WBD Gain Another 20%?If a new bidding war erupts, WBD stands to benefit the most. A $34-per-share offer would represent roughly a 20% premium over WBD's Jan. 8 closing price of $28.32. Notably, the highest analyst price target on WBD, from Arete Research, is $35 — implying at least one analyst believes the stock could move higher if the bidding continues.
This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $12,600. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM). | 
No comments:
Post a Comment